Willdan Announces Date of Second Quarter 2025 Earnings Release and Conference Call
An online, real-time audio webcast of the quarterly investor conference call will be available on Willdan's website at: Willdan Group Q2 2025 Investor Conference Call. Alternatively, listeners may access the call by dialing 877-407-2988 (or 201-389-0923) at least five minutes prior to the 5:30 p.m. EDT / 2:30 p.m. PDT start time. An online replay of the earnings webcast will be available a few hours after the completion of the call at https://ir.willdangroup.com/events-presentations.
About Willdan
Willdan is a nationwide provider of professional, technical, and consulting services to utilities, government agencies, and private industry. Willdan's service offerings span a broad set of complementary disciplines that include electric grid solutions, energy efficiency and sustainability, energy policy planning and advisory, engineering and planning, and municipal financial consulting. For additional information, visit Willdan's website at www.willdan.com. Follow Willdan on LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250708195979/en/
Contacts
Al Kaschalk / (310) 922-5643akaschalk@willdan.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Nvidia Stock Climb Ahead of AI Earnings Wave as Vast Data Deal Brews
Aug 4 - Nvidia (NASDAQ:NVDA) stock climbed 2% on Monday morning to $177, bouncing back after last week's dip tied to disappointing jobs data. The broader market rose too, offering support to AI-related names. However, with most major tech companies having already reported earnings, investors now await Nvidia's own update on August 27 for more direction on the AI trade. Warning! GuruFocus has detected 5 Warning Signs with NVDA. In the meantime, attention shifts to upcoming earnings from Advanced Micro Devices (NASDAQ:AMD) and Super Micro Computer (NASDAQ:SMCI), due Tuesday. Their reports may offer a glimpse into ongoing demand for AI processors, something Nvidia leads in. Nvidia's chips remain the top pick for training AI models. Beyond earnings, Nvidia appears to be putting capital to work. According to a Reuters report, the company is in talks to invest in AI storage specialist Vast Data, a deal that could value the startup at up to $30 billion. Vast Data supports AI data centers by enabling efficient movement of data across processors, an area that aligns well with Nvidia's infrastructure goals. Broadcom (NASDAQ:AVGO) also saw gains of 1.2% in premarket trading, while AMD rose 2%, suggesting investor confidence in the AI supply chain remains strong. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
19 minutes ago
- Business Wire
Growth in Metadata Management Tools Creates Synergies With Structured Data Solutions
DUBLIN--(BUSINESS WIRE)--The "Structured Data Management Software - Global Strategic Business Report" report has been added to offering. The global market for Structured Data Management Software was estimated at US$65.2 Billion in 2024 and is projected to reach US$99.0 Billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Structured Data Management Software market. What's Powering the Growth in the Structured Data Management Software Market? The growth here is driven by several factors related to digital transformation, data regulations, and AI-readiness. Hybrid cloud architectures connecting on-prem and cloud storage require flexible database layers. Demand for real-time analytics and embedded intelligence drives adoption of columnar stores and vector DB capabilities. Metadata governance and regulatory compliance require unified catalogs and lineage. No/low-code analytics tools are democratizing data access. Finally, integration with ML toolchains and cloud data ecosystems (e.g., lakehouse environments) ensures structured data remains central to enterprise data strategies. What's Sustaining Demand for Structured Data Management in Modern Enterprises? Structured data management software-covering relational DBMS, data warehouses, cataloging tools, and ETL platforms-underpins mission-critical operations, analytics, and compliance. It enables accurate SQL querying, schema enforcement, and optimized storage across transactional systems, BI platforms, and ML pipelines. Advanced offerings now support hybrid-cloud deployment, in-memory processing, and real-time querying to meet modern digital application demands. Are Architecture and Usability Upgrades Modernizing the Stack? Next-gen data platforms support auto-indexing, workload-aware caching, and pushdown compute. Data virtualization layers allow federated access to distributed datasets. Metadata enrichment via automatic tagging, lineage graphing, and data classifications improves governance. DevOps tools-schema-as-code, versioned datasets, CI/CD pipelines-embed data workflows into developer cycles. SQL-aware AI assistants enable natural-language data exploration and analytics generation. Why Are Enterprises Prioritizing Structured Data Solutions? Data-driven decision-making, compliance with data regulations (GDPR, CCPA), and audit reporting require auditable and reliable data stores. Organizations need real-time dashboards and ML-based customer insights in use cases like fraud detection and personalized marketing. Scale-efficiency and ROI considerations drive migration from legacy RDBMS to cloud-native analytics databases. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Adobe, Amazon Web Services (AWS), Ataccama, Broadcom, Cisco Systems and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Cloud Deployment segment, which is expected to reach US$66.8 Billion by 2030 with a CAGR of a 8.4%. The On-Premise Deployment segment is also set to grow at 5.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $17.8 Billion in 2024, and China, forecasted to grow at an impressive 11.5% CAGR to reach $21.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and Asia-Pacific. Segments: Deployment (Cloud Deployment, On-Premise Deployment) Organization Size (SMEs, Large Enterprises) End-Use (BFSI End-Use, Automobile End-Use, Healthcare End-Use, Government End-Use, Manufacturing End-Use, IT & Telecom End-Use, Retail & E-Commerce End-Use, Other End-Uses) Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Structured Data Management Software - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Explosion of Enterprise Data Volumes Spurs Demand for Structured Data Management Tools Shift Toward Cloud-Native Data Platforms Strengthens Business Case for Scalable Software Growth in Data-Driven Decision-Making Fuels Integration of Analytics and BI Functions Adoption of AI and ML in Data Classification and Query Optimization Drives Innovation Compliance Pressures and Data Privacy Laws Accelerate Enterprise Adoption Globally Proliferation of SaaS Models Enables Access to Mid-Market and SMB Segments Hybrid and Multi-Cloud Environments Expand Market for Cross-Platform Data Management Real-Time Data Processing Needs in Finance and E-Commerce Boost Software Demand Integration With Legacy Systems and ERP Suites Enhances Market Versatility Increasing Focus on Data Governance and Integrity Drives Structured Data Architecture Investments Rising Importance of Master Data Management in Complex Organizations Spurs Usage Growth in Metadata Management Tools Creates Synergies With Structured Data Solutions FOCUS ON SELECT PLAYERS | Some of the 42 companies featured in this Structured Data Management Software market report include: Adobe Amazon Web Services (AWS) Ataccama Broadcom Cisco Systems Fujitsu Hewlett Packard Enterprise IBM Informatica Microsoft Oracle OpenText RACKSPACE Technology Salesforce SAP SE SAS Institute Teradata Google Ontotext For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Business Wire
19 minutes ago
- Business Wire
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
BUSINESS WIRE)-- Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGI cTouch™ Sirolimus-Coated Balloon for Treatment of C oronary A rtery L esions in S mall V essels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA's IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical's mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. Dr. Samin Sharma enrolled the first patient at New York's Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease. 'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouch as a potential alternative for treating small vessels in the U.S.' Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., across coronary and peripheral interventions, underscoring its commitment to bringing innovative therapies to patients worldwide. MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to DES (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months. An international team of renowned cardiologists, Dr. Martin B. Leon (USA) - Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe) will lead the MAGICAL-SV trial. Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for SCB technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.' Prof. Antonio Colombo, who leads the European arm, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.' This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.' The pioneering MAGICAL-SV trial aims to yield strong clinical evidence for sirolimus-coated balloon therapy, supporting Pre-Market Approval (PMA) for MagicTouch SCB in small vessels and potentially redefining CAD treatment. Dr. Manish Doshi, Founder and MD of Concept Medical, said, "MAGICAL-SV marks another step in our mission to redefine vascular care. We're focused on delivering next-generation solutions, helping clinicians achieve better outcomes and give CAD patients a better quality of life."
